Proclaim-Cx-072: Analysis Of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With Cx-072, A Pd-L1 Probody Therapeutic, As A Single Agent Or In Combination With Ipilimumab.

Fiona Thistlethwaite,Aung Naing,Marta Gil-Martin,Patricia LoRusso,Manreet Randhawa,Ferry Eskens,Rachel E. Sanborn, Nataliya Volodymyrivna Uboha,Daniel C. Cho,Alexander I. Spira,Igor Bondarenko,Elizabeth Ruth Plummer,Javier Garcia-Corbacho,Iván Victoria,Javier Lavernia,Ignacio Melero,Elisabeth De Vries,William Garner,Hendrik-Tobias Arkenau,Johanna C. Bendell

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览60

暂无评分

摘要

3005Background: Monotherapy with immune checkpoint inhibitors (ICIs) has demonstrated efficacy in many cancers. Combining ICIs PD-L1 + CTLA-4 enhanced efficacy but worsened toxicity vs monotherapy;...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要